Analysts Holding As Pfizer Waits On Two Phase 3 Studies
Pfizer has two products with great potential, waiting on phase-3 study results. The resulting revenue increase should also improve share value.
Pfizer has two products with great potential, waiting on phase-3 study results. The resulting revenue increase should also improve share value.